Biogen in pact with NeuroSense for ALS biomarker study
designer491/iStock via Getty Images

Israel-based biotech NeuroSense Therapeutics (NASDAQ:NRSN) announced a collaboration with a subsidiary of Biogen (NASDAQ:BIIB) on Tuesday to jointly run a biomarker study to evaluate the effects of its lead asset PrimeC in patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS).

The news on the agreement sent NeuroSense (NRSN) shares ~8% higher in the pre-market trading Tuesday.
Per the terms of the deal signed in May, Biogen MA Inc., a unit of Biogen (BIIB), will assess PrimeCâs impact on plasma neurofilament levels in patients with ALS in NeuroSenseâs (NRSN) Phase 2b clinical trial, PARADIGM.
Biogen (BIIB) will fund the biomarker study and analyze the results. The Alzheimerâs drugmaker will also have the right of first refusal to a potential licensing deal to develop and commercialize PrimeC for ALS jointly.


More on NeuroSense

NeuroSense Therapeutics surges 92% on Alzheimer's biomarker study results
NeuroSense climbs 56% on promising biomarker data for ALS candidate